Pharmacokinetics of quinapril in patients with renal dysfunction

https://doi.org/10.1016/S0011-393X(05)80696-4Get rights and content

Abstract

The pharmacokinetic properties of quinapril were evaluated in 6 hypertensive patients with normal renal function (group A), 4 hypertensive patients with mild-to-moderate renal dysfunction (group B), and 3 hypertensive patients with severe renal dysfunction (group C). Assessments were made after patients received a single oral 10-mg dose of quinapril and after they received 8 consecutive days of treatment. The peak drug level and the area under the curve for quinaprilat (the active metabolite of quinapril) were 2 to 4 times higher in group C than in group A after 8 days of treatment; this difference was statistically significant. A significant correlation between the area under the curve and serum creatinine levels was observed after the single dose and after 8 days of treatment. Based on our results, we recommend that patients with renal dysfunction receive only half the dose of quinapril administered to patients with normal renal function.

References (16)

  • KaplanHR et al.

    CI-906 and CI-907: New orally active nonsulfhydryl angiotensin-converting enzyme inhibitors

  • Maclean K.Quinapril

    A double-blind placebo-controlled trial in essential hypertension

    Angiology

    (1989)
  • SchnaperHW

    Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension

    Angiology

    (1989)
  • TaylorSH

    A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension

    Angiology

    (1989)
  • FukiyamaK et al.

    A clinical phase-I study of quinapril

    Jpn Pharmacol Ther

    (1991)
  • OnoyamaK et al.

    Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure

    Hypertension

    (1981)
  • ShionoiriH et al.

    Blood concentration and urinary excretion of enalapril in patients with chronic renal failure

    Jpn J Nephrol

    (1985)
  • OnoyamaK et al.

    Pharmacokinetic properties of a new angiotensin I converting enzyme inhibitor in patients with chronic renal failure

    Curr Ther Res

    (1986)
There are more references available in the full text version of this article.

Cited by (0)

View full text